Factor XIa Learning Center
The Evolving Role of Anticoagulation in Acute Coronary Syndromes, Atrial Fibrillation, Secondary Stroke Prevention

Your Clinician-Focused Hub for Factor XIa Pathway Inhibition

Through expert interviews, interactive case discussions, multidisciplinary panels, and patient perspectives, leading authorities in thrombosis, cardiology, neurology, and hematology explore the rapidly evolving landscape of Factor XIa inhibition. Gain access to the latest scientific insights and clinical trial evidence shaping a new era of anticoagulation—one aimed at maintaining protection against thrombotic events while minimizing bleeding risk. Empower clinicians with practical strategies to individualize antithrombotic care, optimize safety and efficacy in high-risk populations, and translate emerging evidence into confident, real-world application.

Educational Activities

CME programs exploring Factor XIa pathway inhibition in acute coronary syndromes, secondary stroke prevention, and atrial fibrillation.

CME Activity • 90 min

Factoring Solutions to the Management of Stroke Care in the Settings of Secondary Prevention and AF

CME Activity • 60 min

Driving Progress in Cardiology: Exploring the Role of FXI in Acute Coronary Syndromes & Beyond

Key Statistics

Understanding the scope and impact of thrombotic and bleeding complications.

1 in 0

Every year, 1 in 4 people worldwide die from conditions related to thrombosis

0.0M

People in the U.S. are hospitalized with acute coronary syndromes yearly, with recurrence rates of 4.4-6.7%

1 in 0

Americans are estimated to be affected by atrial fibrillation, with untreated patients 5x more likely to have a stroke than those without

5th leading cause of death

795,000 stroke events occur yearly in America, with the risk of recurrent stroke in someone who has already had one is 6-15x higher than the risk in the general population

Increased ICH Risk

Amongst DOAC users' risk of ICH is 0.07-0.5%, which becomes impactful at scale in aging populations

Key Takeaway

Bleeding is a significant problem and we need solutions that address this across Atrial Fibrillation, Acute Coronary Syndromes, and Secondary Stroke Prevention.

Expert Faculty & Steering Committee

Our distinguished expert faculty brings together leading authorities in cardiology, thrombosis research, stroke prevention, and clinical trials from premier institutions worldwide.